Activation of B-CLL cells by anti CD180 monoclonal antibodies: Responder and non-responder patients.

被引：0
|
作者：
Porakishvili, N
Slovick, A
Jewell, AP
Youinou, PY
Nathwani, A
Yong, K
Stevenson, F
Clark, EA
Lydyard, PM
机构：
[1] Univ Westminster, Sch Biosci, London, England
[2] Royal Free & UCL Med Sch, London, England
[3] Kingston Univ, Sch Life Sci, Kingston upon Thames KT1 2EE, Surrey, England
[4] Brest Univ, Brest, France
[5] Univ Southampton, Tenovus Res Labs, Southampton SO9 5NH, Hants, England
[6] Univ Washington, Seattle, WA 98195 USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1571
引用
收藏
页码：432A / 432A
页数：1
相关论文
共 50 条
  • [41] A novel anti CD23 fully human monoclonal antibody potentially useful for B-CLL therapy.
    Delcommenne, M
    Klingemann, HG
    Gregory, SA
    BLOOD, 2005, 106 (11) : 343B - 343B
  • [42] CD40 activation of B-CLL cells is associated with augmented intracellular levels of CD79b and increased BCR expression in a subset of patients
    S Minuzzo
    S Indraccolo
    V Tosello
    E Piovan
    A Cabrelle
    L Trentin
    G Semenzato
    A Amadori
    Leukemia, 2005, 19 : 1099 - 1101
  • [43] CD40 activation of B-CLL cells is associated with augmented intracellular levels of CD79b and increased BCR expression in a subset of patients
    Minuzzo, S
    Indraccolo, S
    Tosello, V
    Piovan, E
    Cabrelle, A
    Trentin, L
    Semenzato, G
    Amadori, A
    LEUKEMIA, 2005, 19 (06) : 1099 - 1101
  • [44] Induction of B-CLL apoptosis by monoclonal antibodies against surface IgM is counteracted by CD6 cross-linking.
    Aguilar-Santelises, M
    Osorio, L
    Jondal, M
    Bjorkholm, M
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1998, 13 (01) : 66 - 66
  • [45] The evaluation of Tetanus-diphtheria (Td) vaccine impacts on immune response to hepatitis B (HB) vaccine in non-responder dialysis patients
    Shahidi, Shahrzad
    Ghareghani, Nasrin Namdari
    Mortazavi, Mojgan
    Sadeghi, Somaye
    Adeli, Reza
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2011, 16 (05): : 598 - 604
  • [46] Tocilizumab treatment of MOGAD encephalitis non-responder to Anti CD-20 therapy: efficacy and safety during SARS-COV-2 infection
    Schiro, G.
    Ragonese, P.
    Bianchi, A.
    Andolina, M.
    Iacono, S.
    Salemi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 150 - 150
  • [47] Unresponsiveness of CD4(+) T cells from a non-responder strain to HgCl2 is not due to CD8(+)-mediated immunosuppression: An analysis of the very early activation antigen CD69
    Jiang, Y
    Moller, G
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1996, 44 (06) : 565 - 570
  • [48] LOW-DOSE INTERLEUKIN-2 THERAPY NORMALIZES THE NON-RESPONDER STATE OF DIALYSIS PATIENTS TO HEPATITIS-B VACCINATION
    KOHLER, H
    DUMANN, H
    ZUMBUSCHENFELDE, KHM
    MEUER, SC
    KIDNEY INTERNATIONAL, 1989, 35 (01) : 370 - 370
  • [49] Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B: Results of an open, controlled trial
    Jaboli, MF
    Fabbri, C
    Liva, S
    Azzaroli, F
    Nigro, G
    Giovanelli, S
    Ferrara, F
    Miracolo, A
    Marchetto, S
    Montagnani, M
    Colecchia, A
    Festi, D
    Reggiani, LB
    Roda, E
    Mazzella, G
    WORLD JOURNAL OF GASTROENTEROLOGY, 2003, 9 (07) : 1491 - 1495
  • [50] Pegylated interferon alpha2b plus ribavirin in non responder and naive chronic hepatitis C patients.
    Ripault, MP
    Martinot, M
    Boyer, N
    Giuily, N
    Castelnau, C
    Pouteau, M
    Tarik, A
    Marcellin, P
    HEPATOLOGY, 2002, 36 (04) : 596A - 596A
12345